Apex Biotechnology Corp. (TPE:1733)

Market Cap	2.93B -7.0%
Revenue (ttm)	1.91B -2.8%
Net Income	182.14M +13.2%
EPS	1.81 +13.2%
Shares Out	99.95M
PE Ratio	16.19
Forward PE	n/a
Dividend	1.30 (4.44%)
Ex-Dividend Date	Jun 9, 2026

Volume	103,664
Open	29.35
Previous Close	29.25
Day's Range	29.15 - 29.35
52-Week Range	27.00 - 38.70
Beta	0.26
Analysts	Hold
Price Target	36.00 (+22.87%)
Earnings Date	Aug 10, 2026

About Apex Biotechnology

Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health services. The company was incorporated in 1997 and is based in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1733

Financial Performance

In 2025, Apex Biotechnology's revenue was 1.94 billion, an increase of 5.00% compared to the previous year's 1.85 billion. Earnings were 162.89 million, an increase of 27.26%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error